Nabilone for Non-motor Symptoms in Parkinson's Disease
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
This is an open-label extension study for participants of the randomized placebo-controlled,
double-blind, parallel-group, enriched enrolment randomized withdrawal NMS-Nab Study,
assessing the long-term safety and efficacy of nabilone for non-motor symptoms in patients
with Parkinson´s Disease (PD). Nabilone is an analogue of tetrahydrocannabinol (THC), the
psychoactive component of cannabis. Nabilone acts as a partial agonist on both Cannabinoid 1
(CB1) and Cannabinoid 2 (CB2) receptor in humans and therefore mimics the effect of THC but
with more predictable side effects and less euphoria.
Eligible patients will be re-tapered in an open-label nabilone dose optimization phase
followed by an open-label period of 6 months on a stable nabilone dose.